Biogen

Our team will be at the @asrsdocs Annual Meeting to share 7 research abstracts that highlight our understanding of geographic atrophy (GA), a leading cause of blindness. Stop by Booth #1101 to learn more about our work in GA.

#News: Together with Eisai, we announced that the FDA has approved a new delivery option for people living with early Alzheimer’s disease. Learn more: bit.ly/4wGKCeL

#News: We’re attending the @alzassociation’s International Conference (#AAIC26) to share new data from our Alzheimer’s disease portfolio—including initial data from the Phase 2 study of our investigational tau-targeting therapy. Learn more: bit.ly/4eyKc3U

We’re in San Diego this week at #BIO2026 and look forward to connecting with biotech leaders from across the globe who share our ambition to deliver medicines to help transform patients’ lives. Learn about our partnering opportunities around the world: bit.ly/4gudEJC

At the @ATCMeeting, we're sharing new data on our investigational therapy designed to target CD-38 cells in antibody-mediated rejection. Join us to learn about our ongoing research in kidney transplantation and our late-stage clinical trials. Learn more: ow.ly/MNtN50ZcR2t

#News: Today, we announced an agreement to acquire RayThera Inc. With this deal, we aim to add multiple immunology assets to our portfolio that will contribute to our long-term pipeline potential. Read more about this deal: ow.ly/ogXF50Ze1H3

#News: Today, we announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for an investigational therapy for spinal muscular atrophy (SMA). Learn more about this important milestone: bit.ly/49B9vj0

#News: With @ucb_news, we announced data at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, for an investigational therapy for systemic lupus erythematosus (SLE). Learn more about the data: bit.ly/4uTeELQ

#News: Today we announced we’re sharing 14 abstracts highlighting data from our nephrology portfolio at the European Renal Association (ERA) and American Transplant Congresses (ATC). Read more about our upcoming kidney presentations: bit.ly/4ug63Sm

We’re attending the @ERAkidney Congress to share data on our investigational therapy targeting CD-38 cells in immune-mediated diseases. Join us to learn about our ongoing research and late-stage pipeline: ow.ly/rEhj50Z6Oyr

We’re joining the global rheumatology community at @eular_org to share our latest research focused on systemic lupus erythematosus (SLE). Find us at #EULAR2026 and learn more about our work in lupus: ow.ly/2VH250Z6GX3

#News: With @ucb_news, we’re pleased to share that @TheLancet has published full results from a positive Phase 3 study for an investigational treatment for systemic lupus erythematosus (SLE). Read more: bit.ly/4a07FYY

At #CMSC2026, we’re sharing new data evaluating real-world effectiveness of multiple sclerosis (MS) fumarates therapies.

#News: We announced topline results from a Phase 2 study for an investigational drug targeting tau in individuals with early Alzheimer’s disease. These results represent an important milestone for the field. Learn more: bit.ly/4uemzD8

#News: Today, we announced the successful completion of the acquisition of Apellis Pharmaceuticals. Learn more about this news: bit.ly/3Rbo1HE

STARTING SOON: Join our Q1 2026 financial results live webcast at 8AM ET. Join here: bit.ly/4w1kY4Y #Earnings $BIIB

Today, we reported our Q1 results which reflect our meaningful progress advancing the New Biogen, focused on strong commercial and pipeline execution. Read more: bit.ly/4un5qH7 Forward-looking statements: biogen.com/forward-lookin… #Earnings $BIIB

Meet us at the #ChinaBioPartnering Forum April 28-29 and join our sessions to learn about Biogen’s focus on partnering for global impact and our commitment to innovation from China. Discover our partnering opportunities across the globe: ow.ly/l9go50YP4pb

#News: We announced an agreement with TJ Biopharma to acquire exclusive rights to an investigational treatment for immune-mediated diseases in the Greater China Region. With this, we will now own exclusive worldwide rights to this CD-38 directed antibody. bit.ly/4dYt33E

#News: We announced that we have entered into a definitive agreement to acquire @ApellisPharma. This potential acquisition will bring two best-in-class commercialized immunology medicines to Biogen and accelerate our entry into nephrology. Read more: ow.ly/3PcZ50YB7Pp